awmsg logo



abiraterone (Zytiga®)


Reference No. 3

Publication date:
17/02/2012


Appraisal information

abiraterone (Zytiga®) 250 mg tablet


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 04/01/2012
AWMSG meeting date: 08/02/2012
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 0612
Ministerial ratification: 17/02/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA259). NICE GUIDANCE ISSUED JUNE 2012. (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Abiraterone (Zytiga®) with prednisone or prednisolone is recommended for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. This recommendation applies only in circumstances where the approved Wales Patient Scheme for access to medicines is utilised. AWMSG is of the opinion that abiraterone (Zytiga®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download